Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorPost Graduate Institute of Medical Education and Research, Chandigarh
About this trial
Tirzepatide is a dual agonist of GLP-1 Receptor and the GIP receptor, producing substantial improvement in glycaemic control, weight reduction and insulin sensitivity. Beyond its metabolic effects, incretin signalling has demonstrated neuroprotective and neurotropic properties, including activation of intracellular pathways that enhance neuronal survival and regeneration.
Using tirzapatide for diabetic sensorimotor peripheral neuropathy and assessing with CCM / NCS and BDNF will represent three complementary aspects of nerve regeneration: metabolic control, structural nerve repair and neurotrophic signalling.
Eligibility criteria
Qualifiers
None
Disqualifiers
participants with untreated hypothyroidism
history of leprosy
peripheral vascular disease defined by ankle-brachial index (ABI) < 0.9
serum B12 levels < 200 pg./mL/ if low will be supplemented
Trial design
Treatments tested in this trial
- Tirzepatide 2.5mg weekly
- all standard of care to diabetic patient besides tirzepatide
Treatment groups
40 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov